<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534300</url>
  </required_header>
  <id_info>
    <org_study_id>IVN3ICD</org_study_id>
    <secondary_id>EudraCT number: 2005-002386-37</secondary_id>
    <nct_id>NCT00534300</nct_id>
  </id_info>
  <brief_title>Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker</brief_title>
  <official_title>Intravenous Infusion of n-3 Polyunsaturated Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg Universitetshospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-chain n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA) and
      docosahexaenoic acid (DHA), appear to offer protection against sudden cardiac death and
      ventricular arrhythmias. EPA and DHA are essential fatty acids which are incorporated into
      cellular membranes after regular ingestion of fatty fish or fish oil.

      This study investigates a possible acute effect of intravenous infusion of n-3 PUFA on
      inducibility of ventricular tachycardia (VT) in patients with an ICD-pacemaker.

      The hypothesis is that an acute rise in the concentration of n-3 PUFA in plasma will increase
      the electric stability of the myocardial cells, so that VT is more difficult to induce.

      In a randomized, placebo-controlled, double-blind, crossover study, a lipid emulsion with a
      high content of n-3 PUFA (or placebo: isotonic saline) will be administered intravenously
      before a non-invasive electrophysiologic examination performed via the ICD and following a
      predefined protocol.

      The main outcome is inducibility of VT. If sustained VT is induced in a patient after both
      n-3 PUFA and placebo, the strength of the required stimulus after n-3 PUFA and after placebo
      is compared.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inducibility of ventricular tachycardia</measure>
    <time_frame>Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular repolarization parameters</measure>
    <time_frame>Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of n-3 fatty acids in plasma and platelet membranes</measure>
    <time_frame>Hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Sudden Cardiac Death</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven</intervention_name>
    <description>Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>Intravenous infusion, 100 mL, 25mL/h</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sustained ventricular tachycardia (VT) inducible during primary electrophysiological
             study (before ICD implantation) and one of the following

               -  Latest VT episode terminated by anti-tachycardia pacing (ATP)

               -  VT induced during primary electrophysiological study terminated by ATP

        Exclusion Criteria:

          -  Premenopausal women

          -  Allergy to fish or egg protein

          -  Blood pressure &gt; 160/90 (treated or untreated)

          -  MI, PCI or CABG within the previous 6 months

          -  HbA1c &gt; 10%

          -  ALT &gt; 150 U/L

          -  INR &gt; 3.5

          -  Plasma-potassium &lt; 3.5 mmol/L

          -  Fasting triglycerides &gt; 3 mmol/L

          -  Other serious illness

          -  Inability to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trine Madsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Hospital, Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <last_update_submitted>April 15, 2015</last_update_submitted>
  <last_update_submitted_qc>April 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <name_title>Trine Madsen</name_title>
    <organization>Aalborg Hospital</organization>
  </responsible_party>
  <keyword>ICD-pacemaker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

